Cerebrospinal fluid Apolipoprotein e concentration and progression of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 43, Issue 4, 2014, Pages 1229-1236

  Schmidt, Christian ^a   Gerlach, Nicole ^a   Peter, Christoph ^a   Gherib, Kerim ^a   Lange, Katharina ^a   Friede, Tim ^a   Zerr, Inga ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; apolipoprotein E; biomarker; cerebrospinal fluid; cognition

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BENZODIAZEPINE DERIVATIVE; NOOTROPIC AGENT; TAU PROTEIN; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; DAILY LIFE ACTIVITY; DISEASE COURSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLOBAL DETERIORATION SCALE; HUMAN; INSTRUMENTAL ACTIVITIES OF DAILY LIVING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; OBSERVATIONAL STUDY; PHYSICAL EXAMINATION; PROTEIN CEREBROSPINAL FLUID LEVEL; UNIFIED PARKINSON DISEASE RATING SCALE; CEREBROSPINAL FLUID; COGNITION; FOLLOW UP; MENTAL HEALTH; MOTOR ACTIVITY; PATHOPHYSIOLOGY; REGRESSION ANALYSIS;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; COGNITION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; REGRESSION ANALYSIS;

EID: 84919906607     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141581     Document Type: Article

References (51)

1. Hebert LE,Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80, 1778-1783.
2. Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9, 106-118.
3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, SmallGW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
4. Rogers J, Papassotiropoulos A (2007) A high-density wholegenome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 68, 614-619.
5. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303.
6. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.
7. Chen Y, Durakoglugil MS, Xian X, Herz J (2010) ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci U S A 107, 12011-12016.
8. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541, 163-166.
9. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW (2001) Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A 98, 8838-8843.
10. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD (1994) Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novelmonofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94, 860-869.
11. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM (2000) Apolipoprotein E isoform-dependent amy loid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad SciUS A 97, 2892-2397.
12. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT (2000) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47, 739-747.
13. Hauser PS, Ryan RO (2013) Impact of apolipoprotein E on Alzheimer's disease. Curr Alzheimer Res 10, 809-817.
14. Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, Andreasen N, Nordberg A (2011) The apolipoprotein E 4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging 32, 1236-1248.
15. Merched A, Blain H,Visvikis S, Herbeth B, Jeandel C, SiestG (1997) Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. J Neurol Sci 145, 33-39.
16. Song H, Saito K, Seishima M, Noma A, Urakami K, Nakashima K (1997) Cerebrospinal fluid apo E and apo A-I concentrations in early-and late-onset Alzheimer's disease. Neurosci Lett 231, 175-178.
17. Hahne S, Nordstedt C, Ahlin A, Nybäck H (1997) Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. Neurosci Lett 224, 99-102.
18. Kandimalla RJL, Wani WY, Anand R, Kaushal A, Prabhakar S, Grover VK, Bharadwaj N, Jain K, Gill KD (2013) Apolipoprotein E levels in the cerebrospinal fluid of north Indian patients with Alzheimer's disease. Am J Alzheimers Dis Other Demen 28, 258-262.
19. Blennow K, Hesse C, Fredman P (1994) Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. Neuroreport 5, 2534-2536.
20. Lindh M, BlombergM, Jensen M, Basun H, Lannfelt L, Engvall B, Scharnagel H, März W, Wahlund LO, Cowburn RF (1997) Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett 229, 85-88.
21. Pirttilä T, Koivisto K, Mehta PD, Reinikainen K, Kim KS, Kilkku O, Heinonen E, Soininen H, Riekkinen P,Wisniewski HM (1998) Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease. Neurosci Lett 249, 21-24.
22. Song F, Poljak A, Crawford J, Kochan NA,WenW, Cameron B, Lux O, Brodaty H, Mather K, Smythe GA, Sachdev PS (2012) Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One 7, e34078.
23. Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, Lui JK, Masters C, Rowe CC, Szoeke C, Taddei K, Martins RN (2011) Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging. Neurology 76, 1091-1098.
24. Slooter AJ, de Knijff P, Hofman A, CrutsM,BretelerMM,Van Broeckhoven C, Havekes LM, van Duijn CM (1998) Serum apolipoprotein E level is not increased in Alzheimer's disease: The Rotterdam study. Neurosci Lett 248, 21-24.
25. Liu M, Kuhel DG, Shen L, Hui DY, Woods SC (2012) Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. Am J Physiol Regul Integr Comp Physiol 303, R903-R908.
26. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G,Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
28. Aebi C (2002) Validierung der neuropsychologischen Testbatterie CERAD-NP: Eine Multi-Center Studie. PhD Thesis Fac Humanit Univ Basel Switzerland.
29. Bateman RJ, Wen G, Morris JC, Holtzman DM (2007) Fluctuations of CSF amyloid-beta levels: Implications for a diagnostic and therapeutic biomarker. Neurology 68, 666-669.
30. Lawton MP, Brody EM (1969) Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 9, 179-186.
31. Websource, Basisdokumentation der Aktivitäten des täglichen Lebens (b-ADL), Last updated 2008, Accessed on 2008.
32. Reisberg B, Ferris SH, de Leon MJ, Crook T (1982) The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 139, 1136-1139.
33. Fahn J, Marsden C, Calne D, Goldstein M (1987) Recent developments in Parkinson's Disease. Florham Park Macmillan Healthc Inf 2 153-163, 293-304.
34. Portet F, Scarmeas N, Cosentino S, Helzner EP, SternY(2009) Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Arch Neurol 66, 1120-1126.
35. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL (2013) Amyloid deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12, 357-367.
36. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ (2010) Diagnosis-independent Alzheimer Disease biomarker signature in cognitively normal elderly people. Arch Neurol 67, 949-956.
37. Kandimalla RJL, Prabhakar S, Binukumar BK, Wani WY, Gupta N, Sharma DR, Sunkaria A, Grover VK, Bhardwaj N, Jain K, Gill KD (2011) Apo-E4 allele in conjunction with A42 and tau in CSF: Biomarker for Alzheimer's disease. Curr Alzheimer Res 8, 187-196.
38. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YAL, van Elk EJ, Scheltens P, van der Flier WM (2009) CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 73, 1353-1358.
39. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66, 638-645.
40. Yamauchi K, Tozuka M, Nakabayashi T, Sugano M, Hidaka H, Kondo Y, Katsuyama T (1999) Apolipoprotein E in cerebrospinal fluid: Relation to phenotype and plasma apolipoprotein E concentrations. Clin Chem 45, 497-504.
41. Rosenberg PB, Mielke MM, Han D, Leoutsakos JS, Lyketsos CG, Rabins PV, Zandi PP, Breitner JCS, Norton MC, Welsh-Bohmer KA, Zuckerman IH, Rattinger GB, Green RC, Corcoran C, Tschanz JT (2012) The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int J Geriatr Psychiatry 27, 1248-1257.
42. Domínguez RO, Marschoff ER, González SE, Repetto MG, Serra JA (2012) Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients. Diabetes Res Clin Pract 98, 68-74.
43. Sanz C, Andrieu S, Sinclair A, Hanaire H, Vellas B (2009) Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 73, 1359-1366.
44. Sanz CM, Hanaire H,Vellas BJ, Sinclair AJ, Andrieu S (2012) Diabetes mellitus as a modulator of functional impairment and decline in Alzheimer's disease. The Real. FR cohort. Diabet Med 29, 541-548.
45. De la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2, 1101-1113.
46. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB (2011) Diabetes mellitus and Alzheimer's disease: Shared pathology and treatment? Br J Clin Pharmacol 71, 365-376.
47. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperlí T, Spanò A, Gallo D, Mungari P, Consoli D, Bosco D (2010) Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 288, 112-116.
48. Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I (2011) Rapidly progressive Alzheimer disease. Arch Neurol 68, 1124-1130.
49. Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, DeKosky ST, Sweet RA (2010) Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr 22, 281-290.
50. Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-Bohmer KA, Breitner JCS, Munger R, Lyketsos CG (2007) Vascular factors predict rate of progression in Alzheimer disease. Neurology 69, 1850-1858.
51. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert M-O, Jicha G a, Nordberg A, Pasquier F, Rabinovici G, Robert P,RoweC, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 13, 614-629.